Regulatory T cells in transplantation: does extracellular adenosine triphosphate metabolism through CD39 play a crucial role?

Transplantation Reviews

Volumn 24, Issue 2, 2010, Pages 52-66

  Salcido Ochoa, F ^a   Tsang, Julia ^b   Tam, Paul ^b   Falk, Kirsten ^c   Rotzschke, Olaf ^d  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d AGENCY FOR SCIENCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALEMTUZUMAB; BELATACEPT; CD39 ANTIGEN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; CD4+ CD25+ T LYMPHOCYTE; CELL COMMUNICATION; CELL CONTACT; CELL TRANSPLANTATION; DRUG MECHANISM; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MEMORY T LYMPHOCYTE; NONHUMAN; NUCLEIC ACID METABOLISM; ORGAN TRANSPLANTATION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SKIN ALLOGRAFT; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 77950865221     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2010.01.002     Document Type: Review

References (212)

1. Cohen D.J., St Martin L., Christensen L.L., et al. Kidney and pancreas transplantation in the United States, 1995-2004. Am J Transplant 2006, 6:1153-1169.
2. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004, 4:378-383.
3. Chapman J.R., O'Connell P.J., Nankivell B.J. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005, 16:3015-3026.
4. Tantravahi J., Womer K.L., Kaplan B. Why hasn't eliminating acute rejection improved graft survival?. Annu Rev Med 2007, 58:369-385.
5. Zinkernagel R.M. Immunology taught by viruses. Science 1996, 271:173-178.
6. Alferink J., Tafuri A., Vestweber D., et al. Control of neonatal tolerance to tissue antigens by peripheral T cell trafficking. Science 1998, 282:1338-1341.
7. Kurts C., Miller J.F., Subramaniam R.M., et al. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 1998, 188:409-414.
8. Ferber I., Schonrich G., Schenkel J., et al. Levels of peripheral T cell tolerance induced by different doses of tolerogen. Science 1994, 263:674-676.
9. Kurts C., Kosaka H., Carbone F.R., et al. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med 1997, 186:239-245.
10. Mosmann T.R., Coffman R.L. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989, 46:111-147.
11. Bettelli E., Korn T., Kuchroo V.K. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 2007, 19:652-657.
12. Jenkins M.K., Chen C.A., Jung G., et al. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol 1990, 144:16-22.
13. + T cells in vitro. Int Immunol 1997, 9:935-944.
14. Chai J.G., Bartok I., Chandler P., et al. Anergic T cells act as suppressor cells in vitro and in vivo. Eur J Immunol 1999, 29:686-692.
15. Sakaguchi S., Sakaguchi N., Asano M., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
16. Asano M., Toda M., Sakaguchi N., et al. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996, 184:387-396.
17. Gershon R.K., Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970, 18:723-737.
18. Gershon R.K., Kondo K. Infectious immunological tolerance. Immunology 1971, 21:903-914.
19. Moller G. Do suppressor T cells exist?. Scand J Immunol 1988, 27:247-250.
20. Green D.R., Webb D.R. Saying the "S" word in public. Immunol Today 1993, 14:523-525.
21. Qin S., Cobbold S.P., Pope H., et al. "Infectious" transplantation tolerance. Science 1993, 259:974-977.
22. +. Int Immunol 1998, 10:775-783.
23. + cell lines. Cell Immunol 1990, 129:478-493.
24. Zhang Z.X., Yang L., Young K.J., et al. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med 2000, 6:782-789.
25. Weiner H.L. The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells. Nat Immunol 2001, 2:671-672.
26. + regulatory T cells in the maintenance of T cell homeostasis. J Exp Med 2004, 200:1123-1134.
27. Jiang H., Chess L. The specific regulation of immune responses by CD8+ T cells restricted by the MHC class Ib molecule, Qa-1. Annu Rev Immunol 2000, 18:185-216.
28. + CTLs by TCR Vbeta-derived peptides bound to HLA-E. J Immunol 2001, 167:3800-3808.
29. - double-negative regulatory T cells. Blood 2005, 105:2828-2835.
30. Chang C.C., Ciubotariu R., Manavalan J.S., et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002, 3:237-243.
31. Ehrenstein M.R., Evans J.G., Singh A., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004, 200:277-285.
32. Lindley S., Dayan C.M., Bishop A., et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005, 54:92-99.
33. +CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005, 174:164-173.
34. + T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005, 105:735-741.
35. + regulatory T cells in patients with multiple sclerosis. J Exp Med 2004, 199:971-979.
36. Nadkarni S., Mauri C., Ehrenstein M.R. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007, 204:33-39.
37. Jonuleit H., Schmitt E., Stassen M., et al. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001, 193:1285-1294.
38. Modigliani Y., Coutinho A., Pereira P., et al. Establishment of tissue-specific tolerance is driven by regulatory T cells selected by thymic epithelium. Eur J Immunol 1996, 26:1807-1815.
39. Bensinger S.J., Bandeira A., Jordan M.S., et al. Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4(+)25(+) immunoregulatory T cells. J Exp Med 2001, 194:427-438.
40. Papiernik M., de Moraes M.L., Pontoux C., et al. Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int.Immunol 1998, 10:371-378.
41. Malek T.R., Yu A., Vincek V., et al. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 2002, 17:167-178.
42. + regulatory T cells. Nat Immunol 2008, 9:632-640.
43. Kretschmer K., Apostolou I., Hawiger D., et al. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005, 6:1219-1227.
44. + regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci U S A 2004, 101:4572-4577.
45. + T regulatory cells. J Immunol 2007, 178:4022-4026.
46. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999, 162:5317-5326.
47. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998, 188:287-296.
48. McHugh R.S., Whitters M.J., Piccirillo C.A., et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002, 16:311-323.
49. Shimizu J., Yamazaki S., Takahashi T., et al. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002, 3:135-142.
50. Huang C.T., Workman C.J., Flies D., et al. Role of LAG-3 in regulatory T cells. Immunity 2004, 21:503-513.
51. Bruder D., Probst-Kepper M., Westendorf A.M., et al. Neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol 2004, 34:623-630.
52. + T cells. Blood 2007, 109:2058-2065.
53. + regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood 2007, 110:1550-1558.
54. Yamaguchi T., Hirota K., Nagahama K., et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 2007, 27:145-159.
55. Seddiki N., Santner-Nanan B., Martinson J., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203:1693-1700.
56. + T reg cells. J Exp Med 2006, 203:1701-1711.
57. Read S., Malmstrom V., Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000, 192:295-302.
58. Deaglio S., Dwyer K.M., Gao W., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007, 204:1257-1265.
59. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007, 110:1225-1232.
60. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
61. + T regulatory cells. Nat Immunol 2003, 4:337-342.
62. +CD25 high regulatory cells in human peripheral blood. J Immunol 2001, 167:1245-1253.
63. + Treg free of contaminating effector cells. Blood 2009, 113:827-836.
64. Mandapathil M., Lang S., Gorelik E., et al. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods 2009, 346:55-63.
65. Schubert L.A., Jeffery E., Zhang Y., et al. Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem 2001, 276:37672-37679.
66. + regulatory T cells. Nat Immunol 2003, 4:330-336.
67. Fontenot J.D., Rasmussen J.P., Gavin M.A., et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005, 6:1142-1151.
68. Fontenot J.D., Rasmussen J.P., Williams L.M., et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005, 22:329-341.
69. Fontenot J.D., Dooley J.L., Farr A.G., et al. Developmental regulation of Foxp3 expression during ontogeny. J Exp Med 2005, 202:901-906.
70. Kim J.M., Rasmussen J.P., Rudensky A.Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007, 8:191-197.
71. + regulatory T cells induces a scurfy-like disease. J Exp Med 2007, 204:57-63.
72. Bennett C.L., Christie J., Ramsdell F., et al. The immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
73. Chatila T.A. Role of regulatory T cells in human diseases. J Allergy Clin Immunol 2005, 116:949-959.
74. Marson A., Kretschmer K., Frampton G.M., et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007, 445:931-935.
75. Zheng Y., Josefowicz S.Z., Kas A., et al. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007, 445:936-940.
76. Bettelli E., Dastrange M., Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci U S A 2005, 102:5138-5143.
77. Wu Y., Borde M., Heissmeyer V., et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006, 126:375-387.
78. Ono M., Yaguchi H., Ohkura N., et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 2007, 446:685-689.
79. + CD4 T cells. Ann NY Acad Sci 2007, 1103:167-178.
80. Sauer S., Bruno L., Hertweck A., et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 2008, 105:7797-7802.
81. Luo X., Zhang Q., Liu V., et al. Cutting edge: TGF-beta-induced expression of Foxp3 in T cells is mediated through inactivation of ERK. J Immunol 2008, 180:2757-2761.
82. + regulatory T cells fail to undergo chromatin remodeling across the proximal promoter region of the IL-2 gene. J Immunol 2004, 173:4994-5001.
83. + regulatory T cells. J Immunol 2004, 172:5287-5296.
84. + regulatory T cells. J Leukoc Biol 2006, 80:145-151.
85. + regulatory T cells. J Immunol 2006, 177:2186-2194.
86. + Tregs. J Clin Invest 2006, 116:2521-2531.
87. + immunoregulatory T cells is antigen nonspecific. J Immunol 2000, 164:183-190.
88. + T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006, 176:1582-1587.
89. + regulatory T cells. J Immunol 2005, 175:4180-4183.
90. + T-cell subset. Blood 2005, 105:2877-2886.
91. Furtado G.C., Curotto de Lafaille M.A., Kutchukhidze N., et al. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med 2002, 196:851-857.
92. + T cell suppressor function. J Immunol 2004, 172:6519-6523.
93. + regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008, 9:239-244.
94. Ermann J., Szanya V., Ford G.S., et al. CD4(+)CD25(+) T cells facilitate the induction of T cell anergy. J Immunol 2001, 167:4271-4275.
95. Nakamura K., Kitani A., Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001, 194:629-644.
96. + T cell activation. Eur J Immunol 2003, 33:3473-3483.
97. + regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 2009, 206:421-434.
98. Grossman W.J., Verbsky J.W., Barchet W., et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004, 21:589-601.
99. + regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005, 174:1783-1786.
100. + regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 2000, 30:1538-1543.
101. + T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004, 172:4676-4680.
102. + T cells. J Immunol 2006, 176:6202-6210.
103. Salcido-Ochoa F., Lechler R.I. Dendritic cells prohibited by anergic T cells acquire tolerogenic properties. Transplant Proc 2002, 34:2851-2854.
104. Chen W., Liang X., Peterson A.J., et al. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008, 181:5396-5404.
105. Tang Q., Adams J.Y., Tooley A.J., et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2006, 7:83-92.
106. + T cells and dendritic cells in vivo. J Exp Med 2006, 203:505-511.
107. + T cells. Nat Immunol 2007, 8:1353-1362.
108. Jonuleit H., Schmitt E., Kakirman H., et al. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp.Med 2002, 196:255-260.
109. +. Immunology 2007, 120:447-455.
110. + T cells. J Immunol 2004, 173:5008-5020.
111. Sitkovsky M.V., Lukashev D., Apasov S., et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004, 22:657-682.
112. Sitkovsky M., Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. Nat Rev Immunol 2005, 5:712-721.
113. Burnstock G., Knight G.E. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 2004, 240:31-304.
114. la Sala A., Ferrari D., Di Virgilio F., et al. Alerting and tuning the immune response by extracellular nucleotides. J Leukoc Biol 2003, 73:339-343.
115. Imai M., Goepfert C., Kaczmarek E., et al. CD39 modulates IL-1 release from activated endothelial cells. Biochem Biophys Res Commun 2000, 270:272-278.
116. Warny M., Aboudola S., Robson S.C., et al. P2Y(6) nucleotide receptor mediates monocyte interleukin-8 production in response to UDP or lipopolysaccharide. J Biol Chem 2001, 276:26051-26056.
117. la Sala A., Ferrari D., Corinti S., et al. Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses. J Immunol 2001, 166:1611-1617.
118. Mariathasan S., Monack D.M. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 2007, 7:31-40.
119. McDermott M.F., Tschopp J. From inflammasomes to fevers, crystals and hypertension: how basic research explains inflammatory diseases. Trends Mol Med 2007, 13:381-388.
120. Idzko M., Hammad H., van Nimwegen M., et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med 2007, 13:913-919.
121. Lasso de la Vega M.C., Terradez P., Obrador E., et al. Inhibition of cancer growth and selective glutathione depletion in Ehrlich tumour cells in vivo by extracellular ATP. Biochem J 1994, 298:99-105.
122. Kaczmarek E., Koziak K., Sevigny J., et al. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 1996, 271:33116-33122.
123. Robson S.C., Sevigny J., Zimmermann H. The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance. Purinergic Signal 2006, 2:409-430.
124. Resta R., Yamashita Y., Thompson L.F. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev 1998, 161:95-109.
125. Zhang N., Yang D., Dong H., et al. Adenosine A2a receptors induce heterologous desensitization of chemokine receptors. Blood 2006, 108:38-44.
126. Erdmann A.A., Gao Z.G., Jung U., et al. Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood 2005, 105:4707-4714.
127. Sitkovsky M.V. T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol 2009, 30:102-108.
128. Koziak K., Sevigny J., Robson S.C., et al. Analysis of CD39/ATP diphosphohydrolase (ATPDase) expression in endothelial cells, platelets and leukocytes. Thromb Haemost 1999, 82:1538-1544.
129. Koziak K., Kaczmarek E., Kittel A., et al. Palmitoylation targets CD39/endothelial ATP diphosphohydrolase to caveolae. J Biol Chem 2000, 275:2057-2062.
130. + regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: a role for P2X7 receptors. J Immunol 2005, 175:3075-3083.
131. Kobie J.J., Shah P.R., Yang L., et al. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5′-adenosine monophosphate to adenosine. J Immunol 2006, 177:6780-6786.
132. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 2001, 41:775-787.
133. Li L., Okusa M.D. Blocking the immune response in ischemic acute kidney injury: the role of adenosine 2A agonists. Nat Clin Pract Nephrol 2006, 2:432-444.
134. Bopp T., Becker C., Klein M., et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 2007, 204:1303-1310.
135. Bodor J., Fehervari Z., Diamond B., et al. Regulatory T cell-mediated suppression: potential role of ICER. J Leukoc Biol 2007, 81:161-167.
136. Bodor J., Fehervari Z., Diamond B., et al. ICER/CREM-mediated transcriptional attenuation of IL-2 and its role in suppression by regulatory T cells. Eur J Immunol 2007, 37:884-895.
137. Dwyer K.M., Deaglio S., Gao W., et al. CD39 and control of cellular immune responses. Purinergic Signal 2007, 3:171-180.
138. + regulatory T cells. J Exp Med 2004, 199:303-313.
139. + T cells on the fate of allografts in the absence of immunosuppression. Transplantation 2005, 79:648-654.
140. Zheng X.X., Sanchez-Fueyo A., Domenig C., et al. The balance of deletion and regulation in allograft tolerance. Immunol Rev 2003, 196:75-84.
141. Hara M., Kingsley C.I., Niimi M., et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001, 166:3789-3796.
142. + regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002, 168:1080-1086.
143. Wood K.J., Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003, 3:199-210.
144. Lechler R.I., Garden O.A., Turka L.A. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol 2003, 3:147-158.
145. +. Transplantation 2005, 79:1310-1316.
146. + regulatory T cells that prevent allograft rejection does not compromise immunity to a viral pathogen. J Immunol 2005, 174:3290-3297.
147. Waldmann H., Graca L., Cobbold S., et al. Regulatory T cells and organ transplantation. Semin Immunol 2004, 16:119-126.
148. Demirkiran A., Kok A., Kwekkeboom J., et al. Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transpl 2006, 12:277-284.
149. + T cells in human kidney transplant recipients. J Am Soc Nephrol 2003, 14:1643-1651.
150. Brouard S., Mansfield E., Braud C., et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A 2007, 104:15448-15453.
151. +T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006, 81:398-407.
152. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562.
153. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998, 10:1969-1980.
154. + regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003, 198:235-247.
155. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99:3493-3499.
156. Levings M.K., Sangregorio R., Roncarolo M.G. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001, 193:1295-1302.
157. Godfrey W.R., Ge Y.G., Spoden D.J., et al. In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 2004, 104:453-461.
158. Hoffmann P., Eder R., Kunz-Schughart L.A., et al. Large-scale in vitro expansion of polyclonal human CD4(+)CD25 high regulatory T cells. Blood 2004, 104:895-903.
159. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003, 9:1144-1150.
160. + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003, 112:1688-1696.
161. + regulatory T cells. J Immunol 2003, 170:3939-3943.
162. + regulatory T cells. Nat Med 2005, 11:1238-1243.
163. + immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J Immunol 2006, 176:1266-1273.
164. Green E.A., Choi Y., Flavell R.A. Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 2002, 16:183-191.
165. + regulatory T cells is antigen-specific and requires IL-10 and TGF-beta. J Immunol 2005, 175:4283-4291.
166. Tang Q., Henriksen K.J., Bi M., et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004, 199:1455-1465.
167. + antigen-specific regulatory T cells. Proc Natl Acad Sci U S A 2004, 101(Suppl 2):14622-14626.
168. + regulatory T cells ex vivo. Blood 2003, 102:2180-2186.
169. + regulatory T cells with indirect allospecificity: potential reagents to promote donor-specific transplantation tolerance. Transplantation 2006, 82:1738-1743.
170. + regulatory T cells promote experimental transplantation tolerance. Blood 2007, 109:827-835.
171. + regulatory T cells with indirect allospecificity. Int Immunopharmacol 2006, 6:1883-1888.
172. + T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 2004, 199:1467-1477.
173. + regulatory T cells from nonobese diabetic mice. J Immunol 2005, 175:3053-3059.
174. Graca L., Cobbold S.P., Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med 2002, 195:1641-1646.
175. Wells A.D., Li X.C., Strom T.B., et al. The role of peripheral T-cell deletion in transplantation tolerance. Philos Trans R Soc Lond B Biol Sci 2001, 356:617-623.
176. + Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest 2008, 118:3619-3628.
177. Rogers N.J., Lechler R.I. Allorecognition. Am J Transplant 2001, 1:97-102.
178. Sanchez-Fueyo A., Domenig C.M., Mariat C., et al. Influence of direct and indirect allorecognition pathways on CD4(+)CD25(+) regulatory T-cell function in transplantation. Transpl Int 2007, 20:534-541.
179. Wise M.P., Bemelman F., Cobbold S.P., et al. Linked suppression of skin graft rejection can operate through indirect recognition. J Immunol 1998, 161:5813-5816.
180. + regulatory T lymphocytes. Nat Med 2008, 14:88-92.
181. Bluestone J.A., Thomson A.W., Shevach E.M., et al. What does the future holds for cell-based tolerogenic therapy?. Nat Rev Immunol 2007, 7:650-654.
182. Zhou X., Bailey-Bucktrout S.L., Penaranda C., et al. Instability of the transcription factor Forp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009, 10:1000-1007.
183. + regulatory T cells in human thymus and periphery. Immunity 2008, 28:870-880.
184. + T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci U S A 2009, 106:1903-1908.
185. Bram R.J., Hung D.T., Martin P.K., et al. Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol 1993, 13:4760-4769.
186. Blaha P., Bigenzahn S., Koporc Z., et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 2006, 101:2886-2893.
187. Smiley S.T., Csizmadia V., Gao W., et al. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction. Transplantation 2000, 70:415-419.
188. Li Y., Zheng X.X., Li X.C., et al. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998, 66:1387-1388.
189. Mantel P.Y., Ouaked N., Ruckert B., et al. Molecular mechanisms underlying FOXP3 induction in human T cells. J Immunol 2006, 176:3593-3602.
190. + regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006, 108:390-399.
191. + regulatory T cells in renal transplant recipients. Transplantation 2006, 82:550-557.
192. Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998, 31:335-340.
193. Shibutani S., Inoue F., Aramaki O., et al. Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. Transplantation 2005, 79:904-913.
194. Gregori S., Casorati M., Amuchastegui S., et al. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001, 167:1945-1953.
195. + regulatory T cells in transplantation: progress, challenges and prospects. Am J Transplant 2007, 7:1457-1463.
196. Zheng X.X., Sanchez-Fueyo A., Sho M., et al. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003, 19:503-514.
197. Guillot-Delost M., Cherai M., Hamel Y., et al. Clinical-grade preparation of human natural regulatory T-cells encoding the thymidine kinase suicide gene as a safety gene. J Gene Med 2008, 10:834-846.
198. + regulatory T cells cultured with rapamycin. J Immunol 2007, 178:320-329.
199. + regulatory T-cells. Diabetes 2008, 57:2341-2347.
200. Monk N.J., Hargreaves R.E., Marsh J.E., et al. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat Med 2003, 9:1275-1280.
201. + T cells. J Immunol 2006, 177:944-949.
202. Nikolaeva N., Bemelman F.J., Yong S.L., et al. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation 2006, 81:445-454.
203. + regulatory T cells. Blood 2005, 105:4743-4748.
204. Dodge I.L., Demirci G., Strom T.B., et al. Rapamycin induces transforming growth factor-beta production by lymphocytes. Transplantation 2000, 70:1104-1106.
205. Gao W., Lu Y., El Essawy B., et al. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007, 7:1722-1732.
206. Larsen C.P., Pearson T.C., Adams A.B., et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005, 5:443-453.
207. Chavez H., Beaudreuil S., Abbed K., et al. Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with belatacept mediated CD28-CD80/86 blockade. Transpl Immunol 2007, 17:243-248.
208. + regulatory T-cell pool is present in renal transplant recipients. Am J Transplant 2007, 7:249-255.
209. Vlad G., Ho E.K., Vasilescu E.R., et al. Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation. Transpl Immunol 2007, 18:13-21.
210. Morales J., Bono M.R., Fierro A., et al. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells. Transplant Proc 2008, 40:3223-3228.
211. + regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008, 8:793-802.
212. + regulatory T cells in vitro. Blood 2008, 111:3675-3683.